SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today ...
Leverages HeartBeam AIMIGo™ Platform to Address the Multibillion-Dollar Global Market for Detection of Atrial Arrhythmias SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a ...
Medical Device Network on MSN
FDA clears HeartBeam’s at-home arrhythmia assessment tool
HeartBeam’s ECG software duplicates the 12-lead ECG approach undertaken in healthcare settings with electrodes to evaluate heart arrhythmias.
The company's products, HeartBeam AIMI and HeartBeam AIMIGo, are being developed with the aim of providing accurate diagnostic tools for heart attack detection anytime and anywhere. The core ...
Patented Technology Provides Protection for HeartBeam AIMIGo Credit Card-sized Device in European Market HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and ...
3D Vector ECG Collection Device Slated for FDA 510k Submission in the Fourth Quarter of 2022 SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital ...
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent ...
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback